Login to Your Account

Analysts a-'quiver' about Arrowhead HBV therapy; early phase IIa promising

By Randy Osborne
Staff Writer

Wednesday, August 13, 2014
A morsel of phase IIa data from Arrowhead Research Corp. left investors wanting more and sparked analyst speculation about the potential of the firm's ARC-520, an RNAi-based candidate for hepatitis B virus (HBV).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription